SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR) Files An 8-K Submission of Matters to a Vote of Security Holders

12

SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

On October 3, 2017, Semler Scientific, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) at the offices of Cooley LLP, 101 California Street, Floor 5, San Francisco, California 94111. At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on September 1, 2017. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter.

Proposal 1. Stockholders elected the following nominee to serve as the sole Class II Director on the Company’s board of directors (the “Board”) until the Company’s 2020 Annual Meeting of Stockholders or until his successor has been duly elected and qualified. The voting results for the nominee were as follows:

Director Name Votes For Votes Against Votes Withheld Broker Non- Votes Percentage of Votes in

Favor

Arthur “Abbie” Leibowitz, M.D., F.A.A.P. 2,063,117 4,232 540,207 1,254,221 79.12 %

Proposal 2. Stockholders ratified the selection by the Audit Committee of the Board of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017. The voting results were as follows:

Votes For Votes Against Abstentions Percentage of Votes in Favor
3,861,777 100.00 %


About SEMLER SCIENTIFIC, INC. (OTCMKTS:SMLR)

Semler Scientific, Inc. develops, manufactures and markets products and services that assist healthcare insurers and physician groups in evaluating and treating chronic diseases. The Company markets QuantaFlo and WellChec to its customers. QuantaFlo is an approximately four-minute in-office blood flow test. The routine office usage of the QuantaFlo has ranges from few tests per week to over 10 tests per day. The Company also offers contracts in which it invoices on a per test basis for use of QuantaFlo, or as part of the WellChec multi-test platform. WellChec is the Company’s multi-test service platform. WellChec provides testing equipment and third-party personnel to perform tests and examinations of patients for the Company’s customers. The tests performed are for chronic disease states, which include respiratory disease, vascular disease, eye disease, bone disease, heart disease, neuropathy and diabetes.

An ad to help with our costs